In short
MRT1801 is an investigational mRNA vaccine being studied as a potential treatment for moderate to severe acne. The substance is currently in a Phase 1/2 clinical trial that plans to enrol 549 adults. The trial is authorised and is evaluating the vaccine's safety, efficacy, and immunogenicity when given as an intramuscular injection.
MRT1801 is an investigational mRNA vaccine being studied for the treatment of moderate to severe acne. The substance is currently in a Phase 1/2 clinical trial that plans to enrol 549 adult participants. The trial is authorised and is evaluating the safety, efficacy, and immunogenicity of the vaccine when given as an intramuscular injection.
Key points
- MRT1801 is an investigational mRNA vaccine for moderate to severe acne.
- The single registered trial is in Phase 1/2 and is currently authorised.
- The trial plans to enrol 549 adult participants.
- The vaccine is given by intramuscular injection.
- The study measures safety, efficacy against acne lesions, and immunogenicity.
What is MRT1801?
MRT1801 is an investigational mRNA vaccine. The name MRT1801 is a development code; no trade name or marketing authorisation is recorded in the trial registry. The substance is being developed for the treatment of acne, a common skin condition. The trial record describes the intervention as an "Acne mRNA vaccine" given by intramuscular injection. No information about the vaccine's chemical class, origin, or marketing authorisation status is provided in the registry data.
How does MRT1801 work?
The registry record for MRT1801 does not describe a mechanism of action. The trial title indicates that the study will evaluate immunogenicity, meaning the vaccine's ability to provoke an immune response. Immunogenicity is a measure of whether the body produces antibodies or immune cells in response to a vaccine. The specific molecular target of MRT1801 is not stated in the available data.
Which conditions is it used or studied for?
- Moderate to severe acne — the trial enrols adults with moderate to severe acne, a skin condition characterised by inflamed and non-inflamed lesions on the face.
How is MRT1801 given?
MRT1801 is given as an intramuscular injection. The trial record lists the intervention as "Acne mRNA vaccine (INTRAMUSCULAR INJECTION)". A diluent of 0.9% sodium chloride solution is listed alongside the vaccine, which is used to prepare the injection. No other pharmaceutical forms or routes of administration are recorded.
What do the clinical trials show?
One clinical trial of MRT1801 is registered. It is a Phase 1/2 interventional study that is currently authorised. The trial plans to enrol 549 adult participants with moderate to severe acne.
The study is divided into sentinel cohorts and main cohorts. The sentinel cohorts (A and B) assess the safety profile of the vaccine. The main cohorts (A and B) evaluate the efficacy of the vaccine. A long-term extension phase assesses long-term safety in the sentinel cohorts and main cohort A.
The primary outcome measures include the number of participants with unsolicited systemic adverse events (AEs), solicited injection site and systemic reactions, unsolicited AEs, medically attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs). Efficacy is measured by the percentage change from baseline in the number of inflammatory and non-inflammatory acne lesions on the face, and the total number of acne lesions on the face. The long-term extension measures SAEs and AESIs.
The trial record does not state who can take part beyond adults with moderate to severe acne. No detailed inclusion or exclusion criteria are provided in the registry data.
What side effects are known?
The registry record for MRT1801 does not provide information about known side effects. The trial is designed to measure safety outcomes, including solicited injection site and systemic reactions, unsolicited adverse events, serious adverse events, and adverse events of special interest. No side effect data from completed studies are available in the current record.
